Prof. Shu-Hang Wang graduated and get PhD from Peking University, then she completed her postdoctoral experience in Mayo Clinic, USA. Now she is an associate professor in Chinese Academy of Medical Sciences & Peking Union Medical College. Prof. Wang focuses on the first-in-human translational medicine of anti-tumor innovative drugs, including cell and gene therapy as well as therapeutic cancer vaccines and other new immunotherapies. She is good at personalized treatment of lung cancer and rare tumors. Her academic part-time jobs include Drug Clinical Trial Inspector of the State Drug Administration, editorial board member of a high-impact thoracic oncology journal (Journal of Thoracic Oncology). As the first or corresponding author, she has published more than 80 articles in international well-known journals such as Cancer Cell, JAMA Oncology, Cancer Discovery and Journal of Thoracic Oncology, with a total impact factor of more than 670. She also directed or participated in some national research projects, like National Key Research and Development Programs, Clinical Trial Capacity Enhancement (GCP) Platform Construction, National Natural Science Foundation, Clinical Translational Funds, ASCO LIFE and other projects. She also is the reviewers of Journal of Clinical Oncology, Journal of Thoracic Oncology, Journal of Hematology and Oncology, Lung Cancer and other international journals of oncology. She is committed to clinical trials and translational research of new anti-tumor drugs, mechanism research of anti-tumor drugs, and research on tumor heterogeneity and immune microenvironment. She focuses on the first human transformation application of anti-tumor innovative drug technology, focuses on the research of new immunotherapy technologies and methods such as anti-tumor cells, genes and therapeutic vaccines, and is good at individualized precision treatment of lung cancer and rare tumors. She like to do basketball.